Dr. Stone Discusses Monitoring MRD in AML

Richard M. Stone, MD
Published Online: Tuesday, Oct 10, 2017



Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in acute myeloid leukemia (AML).

One of the most important questions in AML is the clinical relevance of monitoring MRD, says Stone.

Historically, AML therapy success has been measured based on morphologic assessment of the bone marrow. If there are less than 5% blasts in the marrow, the patient is deemed to be in remission—but researchers now want a way to measure the depth of that remission.
 


Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in acute myeloid leukemia (AML).

One of the most important questions in AML is the clinical relevance of monitoring MRD, says Stone.

Historically, AML therapy success has been measured based on morphologic assessment of the bone marrow. If there are less than 5% blasts in the marrow, the patient is deemed to be in remission—but researchers now want a way to measure the depth of that remission.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication